CLEC-1 promotes early IFN response in cDC1s and favors immune dysregulation during sepsis in mice
It is demonstrated that blocking CLEC-1 using an anti-human CLEC-1 monoclonal antibody mitigates hyperinflammation in CLEC-1 humanized mice and suggests its potential as an immunotherapeutic target.